Biogen to buy Reata for about $6.5 bln (updated)
28/07/2023 12:09
(Changes sourcing)
July 28 (Reuters) - Biogen BIIB.O said it would buy
biotech firm Reata Pharmaceuticals RETA.O for roughly $6.5
billion.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini
Ganguli)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer